BHVN

Biohaven Ltd. is a biopharmaceutical company focused on discovering, developing, and commercializing therapies for neurological and neuropsychiatric diseases. Following the sale of its migraine drug portfolio to Pfizer in 2022, Biohaven has rebuilt its pipeline with programs targeting neuroinflammation, neurodegeneration, and rare neurological disorders. The company's lead programs include investigational therapies for obsessive-compulsive disorder, spinocerebellar ataxia, spinal muscular atrophy, and other conditions with significant unmet needs. Biohaven utilizes platform technologies including its proprietary Proteome Stabilization Program and central nervous system delivery approaches. Founded by Vlad Coric and based in New Haven, Connecticut, Biohaven has a track record of successful drug development including the FDA-approved Nurtec ODT (now owned by Pfizer). The company is well-capitalized following the Pfizer transaction and is advancing multiple clinical programs. Biohaven faces typical biopharma risks including clinical trial uncertainties, regulatory approval challenges, and competition from other neuroscience companies. The company continues to invest in clinical development, strategic partnerships, and business development to build a leading neuroscience portfolio.